Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Seville
Clinical trial register · Spain

Clinical Trials in Seville, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 111 Madrid 100 Valencia 42 Santiago Compostela 30 Seville 30
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca71 Hoffmann-La Roche48 Merck Sharp & Dohme LLC47 Janssen Research & Development, LLC40 Eli Lilly and Company37 Clear sponsor filter
Site location
Barcelona111 Madrid100 Valencia42 Santiago Compostela30 Seville30
All 75 locations
Target enrolment
to

Trials with a site in Seville

30 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
Novartis Pharmaceuticals
Phase 3
188
Santiago Compostela, Sabadell, Seville
2026-08-04
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Pozuelo de Alarcón, Barcelona, Las Palmas GC, Madrid, Seville
2026-06-03
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Santiago Compostela, Seville, Badalona, L'Hospitalet de Llobregat, Santander, Cáceres, Reus, A Coruña
2026-05-11
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Pamplona, Valencia, Barcelona, Seville
2026-03-26
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Palma, Barcelona, Madrid, Seville
2026-03-24
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Santiago de Compostela, Barcelona, Córdoba, Madrid, Pontevedra, Seville
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Santiago Compostela, Huelva, El Palmar, Las Palmas GC, Madrid, Salamanca, Seville, Valencia
2025-10-03
Active, closed
Novartis Pharmaceuticals
Phase 2
138
Granada, El Palmar, Barcelona, Seville
2025-07-03
Recruiting
Novartis Pharmaceuticals
Phase 3
400
El Palmar, Valencia, Barcelona, Córdoba, Madrid, Málaga, Seville
2025-06-23
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Granada, Palma, Barcelona, Granollers, Las Palmas GC, Madrid, Pontevedra, Seville
2025-03-20
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Elche, Cadiz, Badalona, Esplugues, Pamplona, Barcelona, Málaga, Seville
2024-12-09
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Santiago Compostela, Marbella, Toledo, Barcelona, Las Palmas de Gran C, Seville
2024-10-24
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Sabadell, Bilbao, A Coruña, Madrid, Seville, Valencia
2024-06-28
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Granada, L'Hospitalet de Llobregat, Barcelona, El Palmar, Madrid, Seville, Valencia
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Santiago Compostela, Barcelona, Córdoba, Málaga, Seville, Valencia
2024-02-28
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Manises, Barcelona, Girona, Lleida, Lugo, Madrid, Seville
2023-07-06
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Barcelona, Madrid, Murcia, Salamanca, Seville
2023-02-03
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Santiago Compostela, Badalona, L'Hospitalet de Llobregat, Bilbao, Santa Cruz, Barcelona, Madrid, Seville
2022-08-30
Recruiting
Novartis Pharmaceuticals
Phase 2
240
Port de Sagunt, Barcelona, Ciudad Real, Madrid, Seville
2022-08-10
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Cadiz, Seville, Barcelona, Sant Joan Despí, Salt, Alcorcón, Getafe, Majadahonda
2021-12-16
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Ferrol, Santiago Compostela, Seville, Mallorca, Palma, el Prat de Llobregat, L'Hospitalet de Llobregat, Sabadell
2021-11-23
Active, closed
Novartis Pharmaceuticals
Phase 3
129
Barakaldo, Seville
2021-10-05
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Barcelona, Port de Sagunt, Madrid, Málaga, Seville
2021-07-28
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Barcelona, Madrid, Sagunto, Seville, Valencia
2020-12-11
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Pamplona, Barcelona, Madrid, Seville
2019-10-03
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
Badalona, L'Hospitalet de Llobregat, Barcelona, Córdoba, Madrid, Salamanca, Seville, Valencia
2019-06-26
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Donostia / San Sebastian, Barcelona, Madrid, Seville, Valencia
2017-08-23
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Esplugues, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia
2015-11-02
Active, closed
Novartis Pharmaceuticals
Phase 1/2
259
Madrid, Seville, Valencia
2013-10-22
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Vigo, Barakaldo, Madrid, Málaga, Seville, Valencia
2013-07-26
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/seville

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies with a site in Seville that also match the filters currently applied.

How many clinical trials are recruiting in Seville?

17 of the 30 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Seville), 30 studies
PhaseStudiesRecruitingShare
Phase 3221273.3%
Phase 24313.3%
Phase 1/23110%
Phase 4113.3%

Most active sponsors

Lead sponsors with the most studies (Seville)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals3017
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.